Current Report Filing (8-k)
November 18 2022 - 3:31PM
Edgar (US Regulatory)
0001292519
false
0001292519
2022-11-17
2022-11-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
November 17, 2022
Date
of Report (Date of earliest event reported)
INVIVO THERAPEUTICS HOLDINGS CORP.
(Exact Name of Registrant as Specified in
Charter)
Nevada |
001-37350 |
36-4528166 |
(State or Other |
(Commission File Number) |
(IRS Employer |
Jurisdiction of Incorporation) |
|
Identification No.) |
One Kendall Square, Suite B14402
Cambridge, Massachusetts
02139
(Address of Principal Executive Offices)
(Zip Code)
(617)
863-5500
(Registrant’s telephone number, including
area code)
(Former name or former address,
if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant
to Section 12(b) of the Act:
Title of each class |
|
Trading symbol(s) |
|
Name of each exchange on
which registered |
Common Stock, $0.00001 par value per share |
|
NVIV |
|
The Nasdaq Capital Market |
Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ¨
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 17, 2022, InVivo
Therapeutics Holdings Corp. (the “Company”) entered into an amendment to the existing employment agreement dated
December 24, 2018 (the “Employment Agreement”) with Richard Christopher, the Company’s Chief Financial
Officer (the “Amendment”). The Amendment provides for an increase from six (6) to twelve (12) months of
continuation of Mr. Christopher’s health insurance benefits under the Company’s employee group health insurance
plan from the date of termination in the event Mr. Christopher’s employment is terminated by the Company without Cause or
if he terminates his employment for Good Reason (each as defined in the Employment Agreement), in each case prior to, or more than
12 months following, a Change in Control (as defined in the Employment Agreement), unless Mr. Christopher becomes eligible for coverage under a new employer
group’s health plan.
The foregoing description of the Amendment is
qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed herewith as Exhibit 10.1, and
is incorporated by reference herein. Unless otherwise specified, capitalized terms used above without definition have the meanings set
forth in the Employment Agreement or the Amendment.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
INVIVO THERAPEUTICS HOLDINGS CORP. |
|
|
Date: November 18, 2022 |
By: |
/s/ Richard Toselli |
|
Name: |
Richard Toselli |
|
Title: |
President and Chief Executive Officer |
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Apr 2024 to May 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From May 2023 to May 2024